Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxybutynin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 0.98 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | PKM | P14618 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | THPO | P40225 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | ESR1 | P03372 | 1/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxybutynin SCHEMBL26033 | 0.99 | CHRM2 (0.96) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL2992 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL1560964 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Aroxybutynin SCHEMBL25880 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Esoxybutynin SCHEMBL290373 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL8019436 | 0.98 | MEN1 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL7895841 | 0.98 | CHRM2 (0.98) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL25751 | 0.98 | MEN1 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL4606219 | 0.98 | CHRM2 (0.98) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Esoxybutynin SCHEMBL5690091 | 0.98 | MEN1 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020142033-A1 | Method for treating incontinence | GUPTA SUNEEL K (US) | 2002-10-03 | — | — | US | disclosed |
| US-20010009995-A1 | Oxybutynin therapy | GUPTA SUNEEL K (US) | 2001-07-26 | — | — | US | disclosed |
| US-6124355-A | SUSTAINED-RELEASE OXYBUTYNIN FORMULATION FOR ORAL ADMINISTRATION TO A PATIENT COMPRISING A THERAPEUTIC DOSE OF AN OXYBUTYNIN | ALZA CORPORATION | 2000-09-26 | — | — | US | disclosed |
| WO-2000019997-A1 | CONTROLLED RELEASE DOSAGE FROM COMPRISING OXYBUTYNIN | ALZA CORPORATION (GB) | 2000-04-13 | — | — | WO | disclosed |
| WO-1999048494-A1 | SUSTAINED-RELEASE COMPOSITION OF OXYBUTYNIN WITH REDUCED XEROSTOMIA EFFECT | ALZA CORPORATION (US) | 1999-09-30 | — | — | WO | disclosed |
| US-5912268-A | DRUG CORE OF OXYBUTYNIN, POLYOXYALKYLENE GLYCOL, AND HYDROXYPROPYL ALKYL CELLULOSE SURROUNDED BY WALL; TIME-RELEASE AGENTS, SIDE EFFECT REDUCTION | ALZA CORPORATION (US) | 1999-06-15 | — | — | US | disclosed |
| US-5840754-A | LESSENING INCIDENCE OF SIDE EFFECTS BY ORALLY ADMINISTERING OXYBUTYNIN FROM CONTROLLED RELEASE DOSAGE FORM TABLET OVER TWENTY-FOUR HOURS | ALZA CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
| US-5674895-A | Dosage form comprising oxybutynin | ALZA CORPORATION (US) | 1997-10-07 | — | — | US | disclosed |
| WO-1996037202-A1 | DOSAGE FORM COMPRISING OXYBUTYNIN | ALZA CORPORATION (US) | 1996-11-28 | — | — | WO | disclosed |